基因检测改善巯嘌呤类药物治疗炎症性肠病的安全性  

Gene Detection Improving Safety of Thiopurine Drugs in Treatment of Inflammatory Bowel Disease

作　　者：刘媛媛[1] 王秋月 李浩[1] 魏良洲[2] LIU Yuanyuan;WANG Qiuyue;LI Hao;WEI Liangzhou(Qingdao University,Qingdao,Shandong Province,266000;Department of Gastroenterology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong Province)

机构地区：[1]青岛大学,266000 [2]青岛大学附属医院消化内科

出　　处：《胃肠病学》2019年第11期695-698,共4页Chinese Journal of Gastroenterology

摘　　要：巯嘌呤类药物如硫唑嘌呤和6-巯基嘌呤,常用于治疗炎症性肠病(IBD)。然而,接受这类药物治疗的患者易出现药物不良反应,其中骨髓抑制最为严重且存在潜在的致命风险。巯嘌呤类药物导致的骨髓抑制具有明显的种族和个体差异。目前,多种遗传标志物被用来鉴定对巯嘌呤类药物敏感的IBD患者。本文就基因检测改善巯嘌呤类药物治疗IBD的安全性作一综述。Thiopurine drugs such as azathioprine and 6-mercaptopurine,are often used in the treatment of inflammatory bowel disease(IBD).However,patients treated with these drugs are prone to adverse drug reactions,in which myelosuppression is the most important and potentially fatal.Currently,multiple genetic markers have been used to identify patients with IBD who are sensitive to thiopurine drugs.This article reviewed the improving of safety of thiopurine drugs in treatment of IBD by gene detection.

关 键 词：炎症性肠病 硫唑嘌呤 巯嘌呤 骨髓抑制 基因检测 安全 

分 类 号：R57[医药卫生—消化系统]